Aptinyx shares crater as lead drug fails in PhII neuropathic pain study
Aptinyx’s approach to modulating the NMDA receptor to treat disorders of the central nervous system has hit a significant snag, as its lead experimental drug failed a mid-stage study in patients with diabetic peripheral neuropathy (DPN), obliterating the recently public company’s stock on Wednesday.
The drug — dubbed NYX-2925 — was developed by the Evanston, IL-based biotech that went public last July banking on its approach to modulate NMDA receptors, which are crucial to brain and nervous system function. The Phase II trial pitted three oral doses of the drug (10 mg, 50 mg, or 200 mg) versus a placebo in 300 patients over four weeks. The experimental treatment failed to confer a statistically significant improvement in average daily pain — as measured by a Numerical Rating Scale (NRS) — at week four, missing the primary endpoint of the study.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters